AAPL316.44+3.05 (+0.97%) ▲|ABBV249.71-3.03 (-1.20%) ▼|ABT94.37-0.82 (-0.86%) ▼|ACN139.05+3.49 (+2.57%) ▲|ADBE222.65+1.71 (+0.77%) ▲|AMAT588.66+18.16 (+3.18%) ▲|AMD546.72+29.32 (+5.67%) ▲|AMGN363.62-4.37 (-1.19%) ▼|AMT164.99-0.05 (-0.03%) ▼|AMZN247.04+3.42 (+1.40%) ▲|AVGO401.11+12.42 (+3.20%) ▲|AXP346.72+10.33 (+3.07%) ▲|BA223.12-1.83 (-0.81%) ▼|BAC59.24+0.94 (+1.60%) ▲|BKNG175.52+1.23 (+0.71%) ▲|BLK1,019.63+29.29 (+2.96%) ▲|BMY57.94+0.40 (+0.69%) ▲|BNY152.24+2.10 (+1.40%) ▲|BRK-B495.38+0.59 (+0.12%) ▲|C139.57+2.18 (+1.59%) ▲|CAT938.32-9.76 (-1.03%) ▼|CL90.99-2.05 (-2.20%) ▼|CMCSA23.35+0.16 (+0.67%) ▲|COF200.06+8.11 (+4.23%) ▲|COP107.99-2.73 (-2.47%) ▼|COST912.97-40.16 (-4.21%) ▼|CRM162.48-4.11 (-2.46%) ▼|CSCO118.31+4.49 (+3.94%) ▲|CVS102.77-1.70 (-1.63%) ▼|CVX174.04-1.94 (-1.10%) ▼|DE592.78-3.96 (-0.66%) ▼|DHR195.83+5.06 (+2.65%) ▲|DIS96.17-0.53 (-0.55%) ▼|DUK125.25-1.55 (-1.22%) ▼|EMR137.76+1.28 (+0.93%) ▲|FDX310.92+1.16 (+0.37%) ▲|GD374.61+0.30 (+0.08%) ▲|GE359.06+3.03 (+0.85%) ▲|GEV1,075.80+4.81 (+0.45%) ▲|GILD134.84-0.98 (-0.72%) ▼|GM76.65+0.41 (+0.53%) ▲|GOOG356.24-2.47 (-0.69%) ▼|GOOGL358.89-3.03 (-0.84%) ▼|GS1,056.14+26.50 (+2.57%) ▲|HD338.69+2.48 (+0.74%) ▲|HON223.42+3.06 (+1.39%) ▲|IBM295.18-6.87 (-2.27%) ▼|INTC112.54+2.30 (+2.09%) ▲|INTU273.38+1.28 (+0.47%) ▲|ISRG411.55-3.55 (-0.86%) ▼|JNJ259.11-4.30 (-1.63%) ▼|JPM335.40+4.78 (+1.45%) ▲|KO82.62-0.79 (-0.94%) ▼|LIN525.56-2.11 (-0.40%) ▼|LLY1,216.48+0.65 (+0.05%) ▲|LMT518.17-9.80 (-1.86%) ▼|LOW212.94+0.09 (+0.04%) ▲|LRCX353.17+20.02 (+6.01%) ▲|MA523.15+4.16 (+0.80%) ▲|MCD276.48-1.77 (-0.64%) ▼|MDLZ58.30-1.18 (-1.98%) ▼|MDT82.38+0.37 (+0.45%) ▲|META631.48+28.36 (+4.70%) ▲|MMM155.36+0.66 (+0.42%) ▲|MO71.60-1.21 (-1.66%) ▼|MRK125.04-0.95 (-0.75%) ▼|MS222.15+4.08 (+1.87%) ▲|MSFT384.36+1.02 (+0.27%) ▲|MU991.64+42.84 (+4.52%) ▲|NEE87.08-0.36 (-0.41%) ▼|NFLX75.47-0.12 (-0.16%) ▼|NKE42.77-0.12 (-0.28%) ▼|NOW108.83+1.05 (+0.97%) ▲|NVDA202.78-1.34 (-0.66%) ▼|ORCL144.27+3.78 (+2.69%) ▲|PEP137.86-4.64 (-3.25%) ▼|PFE24.25+0.20 (+0.83%) ▲|PG146.83-1.57 (-1.06%) ▼|PLTR129.04-3.18 (-2.41%) ▼|PM181.09-5.98 (-3.20%) ▼|QCOM191.11+4.55 (+2.44%) ▲|RTX195.20+0.29 (+0.15%) ▲|SBUX106.41+2.54 (+2.45%) ▲|SCHW101.89+0.19 (+0.19%) ▲|SO95.14-1.24 (-1.29%) ▼|SPG219.72+0.63 (+0.29%) ▲|T21.03-0.09 (-0.43%) ▼|TMO524.71+14.58 (+2.86%) ▲|TMUS181.48+1.34 (+0.74%) ▲|TSLA406.55+12.62 (+3.20%) ▲|TXN308.53+7.21 (+2.39%) ▲|UBER74.35+0.75 (+1.01%) ▲|UNH431.60+6.00 (+1.41%) ▲|UNP285.00+4.06 (+1.45%) ▲|UPS110.71+0.77 (+0.70%) ▲|USB61.90+0.90 (+1.47%) ▲|V348.08+0.55 (+0.16%) ▲|VZ42.23-0.23 (-0.53%) ▼|WFC86.91+1.35 (+1.58%) ▲|WMT112.21-0.89 (-0.79%) ▼|XOM137.37-3.76 (-2.66%) ▼|AAPL316.44+3.05 (+0.97%) ▲|ABBV249.71-3.03 (-1.20%) ▼|ABT94.37-0.82 (-0.86%) ▼|ACN139.05+3.49 (+2.57%) ▲|ADBE222.65+1.71 (+0.77%) ▲|AMAT588.66+18.16 (+3.18%) ▲|AMD546.72+29.32 (+5.67%) ▲|AMGN363.62-4.37 (-1.19%) ▼|AMT164.99-0.05 (-0.03%) ▼|AMZN247.04+3.42 (+1.40%) ▲|AVGO401.11+12.42 (+3.20%) ▲|AXP346.72+10.33 (+3.07%) ▲|BA223.12-1.83 (-0.81%) ▼|BAC59.24+0.94 (+1.60%) ▲|BKNG175.52+1.23 (+0.71%) ▲|BLK1,019.63+29.29 (+2.96%) ▲|BMY57.94+0.40 (+0.69%) ▲|BNY152.24+2.10 (+1.40%) ▲|BRK-B495.38+0.59 (+0.12%) ▲|C139.57+2.18 (+1.59%) ▲|CAT938.32-9.76 (-1.03%) ▼|CL90.99-2.05 (-2.20%) ▼|CMCSA23.35+0.16 (+0.67%) ▲|COF200.06+8.11 (+4.23%) ▲|COP107.99-2.73 (-2.47%) ▼|COST912.97-40.16 (-4.21%) ▼|CRM162.48-4.11 (-2.46%) ▼|CSCO118.31+4.49 (+3.94%) ▲|CVS102.77-1.70 (-1.63%) ▼|CVX174.04-1.94 (-1.10%) ▼|DE592.78-3.96 (-0.66%) ▼|DHR195.83+5.06 (+2.65%) ▲|DIS96.17-0.53 (-0.55%) ▼|DUK125.25-1.55 (-1.22%) ▼|EMR137.76+1.28 (+0.93%) ▲|FDX310.92+1.16 (+0.37%) ▲|GD374.61+0.30 (+0.08%) ▲|GE359.06+3.03 (+0.85%) ▲|GEV1,075.80+4.81 (+0.45%) ▲|GILD134.84-0.98 (-0.72%) ▼|GM76.65+0.41 (+0.53%) ▲|GOOG356.24-2.47 (-0.69%) ▼|GOOGL358.89-3.03 (-0.84%) ▼|GS1,056.14+26.50 (+2.57%) ▲|HD338.69+2.48 (+0.74%) ▲|HON223.42+3.06 (+1.39%) ▲|IBM295.18-6.87 (-2.27%) ▼|INTC112.54+2.30 (+2.09%) ▲|INTU273.38+1.28 (+0.47%) ▲|ISRG411.55-3.55 (-0.86%) ▼|JNJ259.11-4.30 (-1.63%) ▼|JPM335.40+4.78 (+1.45%) ▲|KO82.62-0.79 (-0.94%) ▼|LIN525.56-2.11 (-0.40%) ▼|LLY1,216.48+0.65 (+0.05%) ▲|LMT518.17-9.80 (-1.86%) ▼|LOW212.94+0.09 (+0.04%) ▲|LRCX353.17+20.02 (+6.01%) ▲|MA523.15+4.16 (+0.80%) ▲|MCD276.48-1.77 (-0.64%) ▼|MDLZ58.30-1.18 (-1.98%) ▼|MDT82.38+0.37 (+0.45%) ▲|META631.48+28.36 (+4.70%) ▲|MMM155.36+0.66 (+0.42%) ▲|MO71.60-1.21 (-1.66%) ▼|MRK125.04-0.95 (-0.75%) ▼|MS222.15+4.08 (+1.87%) ▲|MSFT384.36+1.02 (+0.27%) ▲|MU991.64+42.84 (+4.52%) ▲|NEE87.08-0.36 (-0.41%) ▼|NFLX75.47-0.12 (-0.16%) ▼|NKE42.77-0.12 (-0.28%) ▼|NOW108.83+1.05 (+0.97%) ▲|NVDA202.78-1.34 (-0.66%) ▼|ORCL144.27+3.78 (+2.69%) ▲|PEP137.86-4.64 (-3.25%) ▼|PFE24.25+0.20 (+0.83%) ▲|PG146.83-1.57 (-1.06%) ▼|PLTR129.04-3.18 (-2.41%) ▼|PM181.09-5.98 (-3.20%) ▼|QCOM191.11+4.55 (+2.44%) ▲|RTX195.20+0.29 (+0.15%) ▲|SBUX106.41+2.54 (+2.45%) ▲|SCHW101.89+0.19 (+0.19%) ▲|SO95.14-1.24 (-1.29%) ▼|SPG219.72+0.63 (+0.29%) ▲|T21.03-0.09 (-0.43%) ▼|TMO524.71+14.58 (+2.86%) ▲|TMUS181.48+1.34 (+0.74%) ▲|TSLA406.55+12.62 (+3.20%) ▲|TXN308.53+7.21 (+2.39%) ▲|UBER74.35+0.75 (+1.01%) ▲|UNH431.60+6.00 (+1.41%) ▲|UNP285.00+4.06 (+1.45%) ▲|UPS110.71+0.77 (+0.70%) ▲|USB61.90+0.90 (+1.47%) ▲|V348.08+0.55 (+0.16%) ▲|VZ42.23-0.23 (-0.53%) ▼|WFC86.91+1.35 (+1.58%) ▲|WMT112.21-0.89 (-0.79%) ▼|XOM137.37-3.76 (-2.66%) ▼|
26 C
New York
Thursday, July 9, 2026

Tag: research

BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Compelling BRTX-100 Clinical Data, Leadership Enhancements and Strategic updates

MELVILLE, N.Y., June 18, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, is pleased to announce that its Chief Executive Officer, Lance Alstodt, will be interviewed during the Benzinga All-Access Show today, Wednesday, June 18, 2025, at 10:50 a.m. Eastern time.

Thousands and Wildcard Announce $9M Fundraise Co-Led by Arbitrum Gaming Ventures and Paradigm

MCKINNEY, Texas, June 18, 2025 /PRNewswire/ -- Thousands, a revolutionary web3 protocol that transforms word-of-mouth marketing into a universal attribution infrastructure - together with...

Oklahoma Cancer Specialists and Research Institute Selects BioCareSD and AllyGPO as Primary Drug Distributor and GPO Partner

TULSA, Okla., June 18, 2025 /PRNewswire/ -- Oklahoma Cancer Specialists and Research Institute (OCSRI), a leading independent community oncology practice, has officially selected BioCareSD and AllyGPO as its primary...

HKUST Ranks Among World’s Top 20 and Hong Kong #1 in THE Impact Rankings

HKUST Experts Share Insights at Global Sustainability Development Congress in Istanbul HONG KONG, June 18, 2025 /PRNewswire/ -- The Hong Kong University of Science and...

PureBulk Unveils New Filler-Free Electrolyte Mix for Keto Hydration

ROSEBURG, Ore., June 18, 2025 /PRNewswire/ -- PureBulk, a provider of high-purity, clean supplements, today announced the launch of its new product, Tasty Clear...

Beyond Oil Announces Publication of Expert Medical Opinion by Prof. Ilan Ron, Specialist in Clinical and Radiation Oncology, Regarding the Risks Associated with Exposure...

Medical Opinion Concludes that Beyond Oil has Potential to Reduce Gastrointestinal Cancer Risk Among Consumers of Fried Foods and Food Service Workers
Medical Opinion Concludes that Beyond Oil has Potential to Reduce Gastrointestinal Cancer Risk Among Consumers of Fried Foods and Food Service Workers

Flexsys Announces Price Increase for Insoluble Sulfur in India

AKRON, Ohio, June 18, 2025 /PRNewswire/ -- Flexsys has announced that it will increase the price of Insoluble Sulfur products sold in India by...

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

Remepy’s Mobile App Shown to Rewire Brain, Modulate Immune System and Improve Mood in Adults with Subjective Cognitive Decline

RMPY-008 is the first app-based intervention to demonstrate rapid modulation of inflammatory blood biomarkers, acting like a digital antibody in just three weeks Finding from...

Summit Royalty Acquires Cash Flowing Portfolio of Royalties and Stream from IAMGOLD Corporation for $17.5 Million

TORONTO, June 18, 2025 /CNW/ - Summit Royalty Corp. ("Summit" or the "Company"), a private royalty and streaming company, is pleased to announce the successful...

Social and Economic Factors Explain Why Black Patients Lose Less Weight After Bariatric Surgery than Other Groups

NEW YORK, June 18, 2025 /PRNewswire/ -- Weight loss surgery has long been an effective treatment for the more than 40 percent of the American...

President von der Leyen presents Neo’s Made-in-Europe Permanent Magnet to G7 Leaders’ Summit

TORONTO, June 18, 2025 /CNW/ - Neo Performance Materials Inc. ("Neo" or the "Company") (TSX: NEO) (OTCQX: NOPMF) is proud to announce that its Made-in-Europe...

DNS4EU Goes Live, Confirming Strength of Brno’s Cybersecurity Ecosystem, Says Innovation Agency JIC

BRNO, Czech Republic, June 18, 2025 /PRNewswire/ -- The European Union's vision of digital sovereignty enters a new phase with the launch of DNS4EU, a...

Abitibi Metals Announces Phase 3 Drill Strategy and Growth Model Potential

Highlights: Expansion Strategy: The B26 Deposit remains completely open for expansion. Large-scale target areas have been reviewed and prioritized based on their high-grade mineralization potential and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsResearch